Pub Date : 2022-03-22DOI: 10.14302/issn.2690-4837.ijip-22-4342
S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough
Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. Method: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated. Results: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. Conclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them. Keywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety
{"title":"Safety Of BBIBP-CorV (Sinopharm) COVID-19 Vaccination In People With Multiple Sclerosis: A Report From Iran","authors":"S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough","doi":"10.14302/issn.2690-4837.ijip-22-4342","DOIUrl":"https://doi.org/10.14302/issn.2690-4837.ijip-22-4342","url":null,"abstract":"Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. \u0000Method: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated.\u0000Results: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. \u0000Conclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.\u0000\u0000Keywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"27 10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126583322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-14DOI: 10.14302/issn.2690-4837.ijip-22-4080
Fa Oyegbemi, B. Otaigbe, O. Amaewhule
Myiasis is a parasitic infestation of the body of a mammal caused by Cordylobia Anthropophaga (Tumbu fly) larvae. The infestation is prevalent in Sub-Saharan Africa, South-East Mexico and Central America. It is usually seen among rural dwellers and has no age or sex predilection. We report a case of Tumbu fly myiasis seen in a 7month-old male living in Port Harcourt, Nigeria who was erroneously thought to have bullous impetigo.
{"title":"Cutaneous Myiasis Caused by Tumbu Fly Larvae Infestation in an Infant: A Case Report","authors":"Fa Oyegbemi, B. Otaigbe, O. Amaewhule","doi":"10.14302/issn.2690-4837.ijip-22-4080","DOIUrl":"https://doi.org/10.14302/issn.2690-4837.ijip-22-4080","url":null,"abstract":"Myiasis is a parasitic infestation of the body of a mammal caused by Cordylobia Anthropophaga (Tumbu fly) larvae. The infestation is prevalent in Sub-Saharan Africa, South-East Mexico and Central America. It is usually seen among rural dwellers and has no age or sex predilection. We report a case of Tumbu fly myiasis seen in a 7month-old male living in Port Harcourt, Nigeria who was erroneously thought to have bullous impetigo.","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130354265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-27DOI: 10.14302/issn.2690-4837.ijip-21-4015
C. A. C. D. PGDip AMP EHP-C, C. A. C. D. PGDip AMP EHP-C
Copper (Cu) has a strong impact on the function of the immune system through several different pathways. These impacts include helping the function of monocytes, neutrophils, and macrophages, and enhancing Natural Killer cells’ activities. Cu also has a role in antimicrobial properties and inflammatory response. It is also important for IL-2 production and response, which is a component of adaptive immune cells. Additionally, Cu has multiple roles in both proliferation and differentiation of T cells and is involved in the production of antibodies. Cu deficiency can even lead to "increased viral virulence"1. Copper has a long history of use in medicine, and has continued to be used for purification of water, including use in hospitals to prevent legionnaires disease. The CDC pre released information on a study completed in March 2020 on the lifespan of COVID-19 on different surfaces which included its lifespan on copper, where it was completely dead within 4 hours. In addition, "Several reports demonstrated that Cu deficiency weakens the human immune response" 2. Given the multiple avenues of impact, it has been suggested that Cu supplementation, within recommended levels, be given to individuals who are low in Cu to help them fight off COVID-19. It is also possible that Cu supplementation, within recommended levels, may help prevent COVID-19 infection, or help individuals who are not low in Cu to fight off COVID-19 infection. However, dosage would have to be carefully managed, as excess levels of Cu can lead to both neurodegenerative and neurodevelopmental diseases.
{"title":"A Theory on the Impact of Copper and Micronutrients Against COVID-19 in Humans","authors":"C. A. C. D. PGDip AMP EHP-C, C. A. C. D. PGDip AMP EHP-C","doi":"10.14302/issn.2690-4837.ijip-21-4015","DOIUrl":"https://doi.org/10.14302/issn.2690-4837.ijip-21-4015","url":null,"abstract":"Copper (Cu) has a strong impact on the function of the immune system through several different pathways. These impacts include helping the function of monocytes, neutrophils, and macrophages, and enhancing Natural Killer cells’ activities. Cu also has a role in antimicrobial properties and inflammatory response. It is also important for IL-2 production and response, which is a component of adaptive immune cells. Additionally, Cu has multiple roles in both proliferation and differentiation of T cells and is involved in the production of antibodies. Cu deficiency can even lead to \"increased viral virulence\"1. Copper has a long history of use in medicine, and has continued to be used for purification of water, including use in hospitals to prevent legionnaires disease. The CDC pre released information on a study completed in March 2020 on the lifespan of COVID-19 on different surfaces which included its lifespan on copper, where it was completely dead within 4 hours. In addition, \"Several reports demonstrated that Cu deficiency weakens the human immune response\" 2. Given the multiple avenues of impact, it has been suggested that Cu supplementation, within recommended levels, be given to individuals who are low in Cu to help them fight off COVID-19. It is also possible that Cu supplementation, within recommended levels, may help prevent COVID-19 infection, or help individuals who are not low in Cu to fight off COVID-19 infection. However, dosage would have to be carefully managed, as excess levels of Cu can lead to both neurodegenerative and neurodevelopmental diseases.","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115182351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-22DOI: 10.14302/issn.2690-4837.ijip-19-2842
R. Younes, T. F. Farias, Rodrigo A S Sardenberg
Cesarean sections (CS) are one of the most commonly performed surgical procedures worldwide. There is great variability in the percentage of cesarean sections between countries, varying from 3% to 42.9%5. In the US, approximately 32% of deliveries occur through a cesarean section. Overall, a drastic increase in cesarean section rate has been reported reaching its highest level at the present time. In Brazil, considering the types of births by live births from 2006 to 2016, the national percentage of cesarean section was 52.37%. The variability in this percentage can still be perceived within Brazilian territory. The highest cesarean rate occurred in the Southern region, representing 58.33% of births, while the lowest rate occurred in the Northern region, with 41.79%. It is possible to see the steady increase in the percentage of CS over time, from 45.01% in 2006 to 55.39% in 2016.
{"title":"Surgical Site Infection in Cesarean Section Operation: Risk and Management","authors":"R. Younes, T. F. Farias, Rodrigo A S Sardenberg","doi":"10.14302/issn.2690-4837.ijip-19-2842","DOIUrl":"https://doi.org/10.14302/issn.2690-4837.ijip-19-2842","url":null,"abstract":"Cesarean sections (CS) are one of the most commonly performed surgical procedures worldwide. There is great variability in the percentage of cesarean sections between countries, varying from 3% to 42.9%5. In the US, approximately 32% of deliveries occur through a cesarean section. Overall, a drastic increase in cesarean section rate has been reported reaching its highest level at the present time.\u0000\u0000In Brazil, considering the types of births by live births from 2006 to 2016, the national percentage of cesarean section was 52.37%. The variability in this percentage can still be perceived within Brazilian territory. The highest cesarean rate occurred in the Southern region, representing 58.33% of births, while the lowest rate occurred in the Northern region, with 41.79%. It is possible to see the steady increase in the percentage of CS over time, from 45.01% in 2006 to 55.39% in 2016.","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121925697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-03DOI: 10.14302/ISSN.2690-4837.IJIP-18-2515
Rodrigo Sardenberg, R. Younes
Surgical site infections (SSI) have a high incidence, accounting for 20% of all hospital-acquired in-fections. Surgical site infections are linked to a increased length of stay and the risk of mortality. Although most patients recover from an SSI, 77% of mortality can be attributed to the infection it-self 1, 4. The incidence of SSI is 2% to 5% undergoing inpatient surgery 1. Estimated annual in-cidence varies, but may range from 160,000 to 300,000 in the US 1, 4. These estimates might be understated, given the surveillance failure after discharge
{"title":"Surgical Site Infections: A Still Ongoing Challenge","authors":"Rodrigo Sardenberg, R. Younes","doi":"10.14302/ISSN.2690-4837.IJIP-18-2515","DOIUrl":"https://doi.org/10.14302/ISSN.2690-4837.IJIP-18-2515","url":null,"abstract":"Surgical site infections (SSI) have a high incidence, accounting for 20% of all hospital-acquired in-fections. Surgical site infections are linked to a increased length of stay and the risk of mortality. Although most patients recover from an SSI, 77% of mortality can be attributed to the infection it-self 1, 4. The incidence of SSI is 2% to 5% undergoing inpatient surgery 1. Estimated annual in-cidence varies, but may range from 160,000 to 300,000 in the US 1, 4. These estimates might be understated, given the surveillance failure after discharge","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"94 24","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120825192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：